NovelStem Slashes Q1 Net Loss by 73% to $55K, Focuses on License Monetization
NSTM sits 30% above its 52-week low of $0.008.
Summary
NovelStem International Corp. reported a significant improvement in its first-quarter 2026 financial results, narrowing its net loss by 73.4% year-over-year to $(55,021) from $(207,216). The company continues to operate without generating revenue, with its business model centered on monetizing its NewStem license through Yissum. This substantial reduction in net loss, primarily due to lower general, administrative, and legal costs, is a positive development for the micro-cap company, potentially extending its cash runway. Investors will be watching for progress on the commercialization of the NewStem license, as future operational revenue is entirely dependent on its success.
At the time of this announcement, NSTM was trading at $0.01 on OTC in the Life Sciences sector, with a market capitalization of approximately $493.3K. The 52-week trading range was $0.01 to $0.33. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.